Immunic (NASDAQ:IMUX) Releases Quarterly Earnings Results

Immunic (NASDAQ:IMUX) issued its quarterly earnings results on Tuesday. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.36, FiscalAI reports.

Immunic Stock Up 9.8%

Shares of IMUX opened at $15.48 on Wednesday. The stock has a market capitalization of $210.85 million, a P/E ratio of -2.77 and a beta of 1.41. The firm has a fifty day simple moving average of $14.31 and a two-hundred day simple moving average of $11.90. Immunic has a twelve month low of $5.06 and a twelve month high of $15.84.

Institutional Trading of Immunic

A number of hedge funds have recently made changes to their positions in IMUX. Qube Research & Technologies Ltd bought a new position in Immunic during the 3rd quarter valued at approximately $29,000. Two Sigma Investments LP purchased a new position in Immunic in the third quarter worth about $52,000. Virtu Financial LLC bought a new position in shares of Immunic in the third quarter worth approximately $99,000. Jane Street Group LLC grew its holdings in shares of Immunic by 279.3% during the first quarter. Jane Street Group LLC now owns 207,401 shares of the company’s stock valued at $226,000 after buying an additional 152,726 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of Immunic during the fourth quarter valued at approximately $120,000. 51.82% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

IMUX has been the topic of a number of recent analyst reports. LADENBURG THALM/SH SH raised shares of Immunic to a “strong-buy” rating in a research note on Wednesday, July 29th. Wolfe Research initiated coverage on shares of Immunic in a research note on Friday, May 22nd. They issued an “outperform” rating for the company. HC Wainwright reissued a “buy” rating and issued a $22.00 price target (up from $5.00) on shares of Immunic in a report on Thursday, April 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunic in a research report on Friday, May 29th. Finally, D. Boral Capital downgraded shares of Immunic from a “buy” rating to a “hold” rating in a report on Wednesday, April 15th. Three investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $47.57.

About Immunic

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.